Saluda Medical Pty Ltd. is a medical device company focused on developing innovative solutions for the neuromodulation industry. The firm is known for its investigational device, Evoke, which features a closed-loop spinal cord stimulation system. This technology measures the spinal cord's response to stimulation and adjusts the stimulation parameters in real-time to optimize therapeutic outcomes for patients. Founded in 2010 and headquartered in Artarmon, Australia, with additional offices in Minnesota and the United Kingdom, Saluda Medical aims to provide effective treatment for chronic neuropathic pain. The company's unique approach involves monitoring each patient's neural fingerprint to automatically tailor electrical stimulation, ensuring that therapy is customized to meet individual needs. Saluda Medical's commitment to advancing medical technology is underpinned by a strong foundation of scientific research and a team of experienced professionals.
Moving Analytics. is a tele-health company dedicated to helping people thrive after heart disease. Our flagship product is Movn a virtual cardiac rehabilitation program that leverages evidence based guidelines, behavioral science, remote monitoring and personalized coaching to help patients recover to full health after a cardiac event. Movn is currently used by the Veterans Affairs Medical Center, Highmark Health Plan, Kaiser Permanente Northwest and many more health systems across the US.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
Cityblock Health, based in Brooklyn, New York, is a technology-driven healthcare provider focused on serving low-income urban communities with complex needs. Founded in 2017, the company aims to address the unmet health and social needs of Medicaid and Medicare populations through a personalized approach. Cityblock offers primary care, behavioral health, and virtual care services, emphasizing preventive care and mental health support. Its platform integrates communications and information sharing among care teams and members, facilitating better coordination of services. The company also collaborates with community-based organizations to enhance the delivery of care, ultimately seeking to improve health outcomes and reduce costs for its members.
Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Cityblock Health, based in Brooklyn, New York, is a technology-driven healthcare provider focused on serving low-income urban communities with complex needs. Founded in 2017, the company aims to address the unmet health and social needs of Medicaid and Medicare populations through a personalized approach. Cityblock offers primary care, behavioral health, and virtual care services, emphasizing preventive care and mental health support. Its platform integrates communications and information sharing among care teams and members, facilitating better coordination of services. The company also collaborates with community-based organizations to enhance the delivery of care, ultimately seeking to improve health outcomes and reduce costs for its members.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease. It offers HeartFlow Analysis, a non-invasive solution available in the United States, Europe, and Japan that helps a physician evaluate whether a patient has significant coronary artery disease based on anatomy and physiology.
The company was started in 2007 and is based in Redwood City, California.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.